China UnionPay Co (中國銀聯), China’s only credit card network, plans to set up an office in Taiwan in view of increased credit card transactions by Chinese tourists, a top company executive said yesterday.
China UnionPay chief executive officer and president Xu Luode (許羅德) made the statement after inaugurating new services that allow cardholders to pay taxi fares and purchase high speed rail tickets in Taiwan.
“The business of UnionPay cards has progressed quickly and steadily in Taiwan, thanks to -support from both sides of the Taiwan Strait,” Xu said.
The new services came ahead of the government’s relaxation of rules governing independent travel by Chinese tourists, which starts on Tuesday. Currently, Chinese tourists can only travel to Taiwan in tour groups.
Xu said China UnionPay has filed applications with the government to establish an office and conveyed its wish to seek approval to issue credit and debit cards.
At present, UnionPay cardholders can only make payments at about 40,000 contracted stores and use 17,000 of the nation’s automated teller machines (ATM).
Transactions by China UnionPay cardholders in Taiwan totaled 8.2 billion yuan (NT$35.3 billion) between the rollout of the payment service in August 2009 and Monday, Xu said, adding that the figures for the first five months of this year were equal to that for all of last year because more Chinese visited Taiwan.
China UnionPay has entered into cooperative ventures with local taxi service providers and it aims to lift the ATM coverage ratio from the current 70 percent to 80 percent by the end of the month, and to 100 percent in the not too distant future, Xu said.
China UnionPay has 2.5 billion credit and debit cards in circulation in different countries worldwide.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Yageo Corp (國巨), the world’s third-largest supplier of multilayer ceramic capacitors, has formed a strategic alliance with Hon Hai Precision Industry Co (鴻海精密) to develop key electronic components for electric vehicles and digital healthcare, it said yesterday. The alliance is to help Yageo boost its revenue from high-end components for vehicles and industrial, medical and aerospace devices, as well as those used in 5G and Internet-of-Things devices, the company said. The companies signed the strategic alliance agreement at Yageo’s headquarters in New Taipei City’s Sindian District (新店). Their cooperation is to start this quarter, the companies said in a joint statement. “Through the cooperation
SUPPLY CONSTRAINTS: The transferred orders might not provide an immediate revenue boost given local chipmakers’ high utilization rates, a senior analyst said Shares of local contract chipmakers yesterday rose as much as the 10 percent daily limit, as investors bet on orders being transferred from Semiconductor Manufacturing International Corp (SMIC, 中芯國際) after the US imposed export restrictions on the Chinese chipmaker. United Microelectronics Corp (UMC, 聯電) shares soared 10 percent to close at NT$27.5 as 380 million shares changed hands on the Taiwan Stock Exchange. UMC is the world’s No. 3 foundry by revenue, followed by SMIC, according to data from market researcher TrendForce Corp (集邦科技). UMC has product and customer portfolios similar to those of SMIC, TrendForce said, adding that UMC offers 14-nanometer and
‘IMPORTANT MILESTONE’: The firm expects to launch the generic of Revlimid in the US after March 2022. It has already launched the product in some European countries Lotus Pharmaceutical Co Ltd (美時化學製藥) has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for lenalidomide, the company said in a statement on Friday. The ANDA approval is for 2.5mg, 5mg, 10mg, 20mg and 25mg capsules of lenalidomide, which is a generic version of blood cancer drug Revlimid developed by Celgene Corp. It is the first product fully developed and manufactured in Lotus’ facilities in Taiwan. Lotus expects to launch the product in the US — based on its patent litigation settlement with Celgene last year — some time after March